Piloerection induced by replacing fluvoxamine with milnacipran

British Journal of Clinical Pharmacology

Volumn 63, Issue 6, 2007, Pages 665-671

  Hori, Satoko ^a   Matsuo, Nobuko ^b   Yamamoto, Akiko ^b   Hazui, Tomomi ^b   Yagi, Hiromi ^b   Nakano, Marumi ^b   Suzuki, Yuka ^b   Miki, Akiko ^a   Ohtani, Hisakazu ^a   Sawada, Yasufumi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Dream Pharmacy   (Japan)

Author keywords

1 adrenoceptor; Milnacipran; Norepinephrine reuptake inhibition; Piloerection; Receptor occupancy

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; CLORAZEPATE DIPOTASSIUM; DESIPRAMINE; FELBINAC; FLUVOXAMINE MALEATE; IMIPRAMINE; LORAZEPAM; LOXOPROFEN; MECOBALAMIN; MILNACIPRAN; NORADRENALIN; REBAMIPIDE; SULPIRIDE; TIZANIDINE;

ADULT; ARTICLE; CASE REPORT; DEPRESSION; DOSE RESPONSE; DROWSINESS; DRUG DOSE INCREASE; DRUG SUBSTITUTION; FATIGUE; FEMALE; HUMAN; OUTPATIENT DEPARTMENT; PANIC; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REFLEX; SIDE EFFECT;

ADULT; ANTIDEPRESSIVE AGENTS; CYCLOPROPANES; FEMALE; FLUVOXAMINE; HUMANS; IMIPRAMINE; MODELS, BIOLOGICAL; NOREPINEPHRINE; PANIC DISORDER; PILOERECTION;

EID: 34248573946     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02838.x     Document Type: Article

References (31)

1. Lopez-Ibor J, Guelfi JD, Pletan Y, Tournoux A, Prost JF. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 1996 11 (Suppl. 4 41 6.
2. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000 58 : 19 36.
3. Stephens MDB. Drug-induced piloerection in man: an alpha 1-adrenoceptor agonist effect? Hum Toxicol 1986 5 : 319 24.
4. Metligine (midodrine). Package insert. Tokyo : Taisho Toyama Pharma Co. 2005.
5. Mexan (methoxamine). Package insert. Kyoto : Nippon Shinyaku Co. 2005.
6. Sawada Y, Yamada Y, Iga T. Quantitative evaluation of pharmacological effects and adverse effects based on receptor occupancy theory. Yakugaku Zasshi 1997 117 : 65 90.
7. Granfors MT, Backman JT, Neuvonen M, Ahonen J, Neuvonen PJ. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. Clin Pharmacol Ther 2004 75 : 331 41.
8. Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. Br J Clin Pharmacol 2004 57 : 349 53.
9. Tsuruta K, Tsurui K, Okazaki K, Ueda K, Kawasumi S, Shimada N, Sawada Y. Examination of drug-drug interaction of milnacipran hydrochloride in the presence of human P-450. Iyakuhin Kenkyu 2000 31 : 659 67 (Japanese).
10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981 30 : 239 45.
11. Interview form of Tofranil (imipramine). Tokyo : Novartis Pharma Inc. 2006.
12. Luvox (Fluvoxamine Maleate). Package insert. Tokyo : Astellas Pharma Inc. 2006.
13. Toledomin (Milnacipran Hydrochloride). Package insert. Tokyo : Asahi Kasei Pharma Inc. 2006.
14. Koyama E, Otani K, Morinobu S, Ishizaki T. A study of in vitro and in vivo pharmacogenetic metabolism of imipramine in humans. Rinsho Yakuri No Shinpo 2001 22 : 24 34.
15. Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 1984 230 : 94 102.
16. Kitamura Y, Nagatani T, Takao K, Hashimoto S, Kasahara K, Mochizuki D, Yamada S, Sasaki Y, Koyama T. Pharmacological study of milnacipran, a novel antidepressant. Shinkei Seishin Yakuri 1995 17 : 25 34.
17. Beique JC, Lavoie N, de Montigny C, Debonnel G. Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol 1998 349 : 129 32.
18. Wong EH, Sonders MS, Amara SG, Tinholt PM, Piercey MF, Hoffmann WP, Hyslop DK, Franklin S, Porsolt RD, Bonsignori A, Carfagna N, McArthur RA. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 2000 47 : 818 29.
19. Weiss R, Knight BP, Bahu M, Zivin A, Souza J, Goyal R, Daoud E, Man KC, Strickberger SA, Halter JB, Morady F. Cardiac electrophysiologic effects of norepinephrine in human being. Am Heart J 1998 135 : 945 51.
20. Lei B, Morris DP, Smith MP, Svetkey LP, Newman MF, Rotter JI, Buchanan TA, Becjstrom-Sterberg SM, Green ED, Schwinn DA. Novel human alpha1a-adrenoceptor single nucleotide polymorphisms alter receptor pharmacology and biological function. Naunyn Schmiedebergs Arch Pharmacol 2005 371 : 229 39.
21. Lazowick AL, Levin GM. Potential withdrawal syndrome associated with SSRI discontinuation. Ann Pharmacother 1995 29 : 1284 5.
22. Takayanagi I, Konno F, Ishii C, Takemasa T, Yanagida Y, Shimizu M, Mori H. Actions of tizanidine on alpha 1- and alpha 2-adrenoceptors in the peripheral tissues. General Pharmacol 1984 15 : 239 41.
23. Interview form of Ternelin (tizanidine Hydrochloride). Tokyo : Novartis Pharma Inc. 2003.
24. Raezer DM, Wein AJ, Jacobowitz D, Corriere JN Jr. Autonomic innervation of canine urinary bladder. Cholinergic and adrenergic contributions and interaction of sympathetic and parasympathetic nervous systems in bladder function. Urology 1973 2 : 211 21.
25. Briley M, Prost JF, Moret C. Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol 1996 11 (Suppl. 4 9 14.
26. Montgomery SA, Prost JF, Solles A, Briley M. Efficacy and tolerability of milnacipran: an overview. Int Clin Psychopharmacol 1996 11 (Suppl. 4 47 51.
27. Yoshida K, Higuchi H, Takahashi H, Shimizu T. Evaluation of blood pressure induced by high-dose milnacipran. Hum Psychopharmacol Clin Exp 2002 17 : 431.
28. McClellan KJ, Wiseman LR, Wilde MI. Midodrine. A review of its therapeutic use in the management of orthostatic hypotension. Drugs Aging 1998 12 : 76 86.
29. Nakano T, Okamoto K, Inenaga K, Suwaki K, Sasaki K, Ohtsuki S, Yokoyama S, Hisayama C, Watanabe M, Hayashi Y, Shinagawa S, Kuroda K, Hirata J, Syutara M, Edamatsu K, Kisimoto A, Ichikawa M, Hazama H, Fukuda T, Inoue H, Kadonan J, Kashiwagi T, Ishizu H, Ide K, Sarai K, Hikidi A, Morita H, Ishibashi A, Nakamura M, Ogawa Y. A comparative clinical trial of mianserin and imipramine in the treatment of depression. Seishin Igaku 1980 22 : 309 23.
30. Chalothorn D, McCune DF, Edelmann SE, Garcia-Cazarin ML, Tsujimoto G, Piascik MT. Differences in the cellular localization and agonist-mediated internalization properties of the alpha(1)-adrenoceptor subtypes. Mol Pharmacol 2002 61 : 1008 16.
31. Lattion AL, Diviani D, Cotecchia S. Truncation of the receptor carboxyl terminus impairs agonist-dependent phosphorylation and desensitization of the alpha 1B-adrenergic receptor. J Biol Chem 1994 269 : 22887 93.